Palvella Therapeutics (PVLA) Assets Average (2014 - 2026)

Palvella Therapeutics (PVLA) has 13 years of Assets Average data on file, last reported at $161.7 million in Q1 2026.

• Assets Average for Q1 2026 came in at $161.7 million, up 92.83% year-over-year; the trailing twelve-month figure through Mar 2026 was $161.7 million (up 92.83% YoY), and the FY2025 annual result was $73.9 million, up 54.3% from the prior year.
• Assets Average improved to $161.7 million in Q1 2026 per PVLA's latest filing, from $63.2 million in the prior quarter.
• Over five years, Assets Average peaked at $161.7 million in Q1 2026 and troughed at $18.5 million in Q1 2024.
• A 5-year average of $78.5 million and a median of $76.6 million in 2025 frame the typical range for Assets Average.
• The sharpest annual moves came in 2024 and 2025: Assets Average sank 79.16% in 2024, then surged 352.62% in 2025.
• A 5-year view of Assets Average shows it stood at $97.3 million in 2022, then sank by 65.62% to $33.5 million in 2023, then soared by 62.51% to $54.4 million in 2024, then rose by 16.31% to $63.2 million in 2025, then jumped by 155.6% to $161.7 million in 2026.
• Business Quant data shows PVLA's Assets Average at $161.7 million in Q1 2026, $63.2 million in Q4 2025, and $70.3 million in Q3 2025.